Wells Fargo’s Allena Pharmaceuticals ALNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-3,053
Closed 7875
2022
Q2
$0 Buy
3,053
+85
+3% +$13 ﹤0.01% 7945
2022
Q1
$1K Buy
2,968
+16
+0.5% +$7 ﹤0.01% 6930
2021
Q4
$1K Buy
2,952
+1,529
+107% +$1.2K ﹤0.01% 7135
2021
Q3
$1K Buy
1,423
+167
+13% +$164 ﹤0.01% 6879
2021
Q2
$1K Buy
1,256
+31
+3% +$38 ﹤0.01% 6808
2021
Q1
$1K Sell
1,225
-1
-0.1% -$2 ﹤0.01% 6816
2020
Q4
$1K Buy
1,226
+86
+8% +$120 ﹤0.01% 6411
2020
Q3
$1K Buy
1,140
+55
+5% +$77 ﹤0.01% 6260
2020
Q2
$2K Sell
1,085
-2,100
-66% -$3.53K ﹤0.01% 6130
2020
Q1
$3K Buy
3,185
+85
+3% +$170 ﹤0.01% 5966
2019
Q4
$8K Sell
3,100
-9,089
-75% -$29.8K ﹤0.01% 5961
2019
Q3
$48K Buy
12,189
+438
+4% +$1.88K ﹤0.01% 5571
2019
Q2
$48K Sell
11,751
-9,560
-45% -$52.2K ﹤0.01% 5569
2019
Q1
$150K Buy
21,311
+7,283
+52% +$52.8K ﹤0.01% 4964
2018
Q4
$76K Buy
14,028
+7,359
+110% +$63.4K ﹤0.01% 5405
2018
Q3
$72K Buy
6,669
+3,250
+95% +$35.7K ﹤0.01% 5477
2018
Q2
$44K Sell
3,419
-5,917
-63% -$85.3K ﹤0.01% 5631
2018
Q1
$103K Buy
9,336
+6,641
+246% +$55.5K ﹤0.01% 5288
2017
Q4
$27K Buy
+2,695
New +$33.2K ﹤0.01% 5717

Other funds holding ALNA

Wells Fargo's ALNA Position: Q3 2022 in Review

Wells Fargo sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 3,053 shares.

Wells Fargo first reported a position in ALNA in Q4 2017 and held it in 19 quarters. The position peaked at $150K in Q1 2019. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.

  • Wells Fargo reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Wells Fargo sold 3,053 Allena Pharmaceuticals shares in Q3 2022.
  • Wells Fargo first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 19 quarters.
  • Wells Fargo's Allena Pharmaceuticals position peaked at $150K in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.

Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.